Literature DB >> 12146959

Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions.

Jeffrey S Grinstead1, R Rao Koganty, Mark J Krantz, B Michael Longenecker, A Patricia Campbell.   

Abstract

MUC1 mucin is a large transmembrane glycoprotein, of which the extracellular domain is formed by a repeating 20 amino acid sequence, GVTSAPDTRPAPGSTAPPAH. In normal breast epithelial cells, the extracellular domain is densely covered with highly branched complex carbohydrate structures. However, in neoplastic breast tissue, the extracellular domain is underglycosylated, resulting in the exposure of a highly immunogenic core peptide epitope (PDTRP in bold above) as well as the normally cryptic core Tn (GalNAc), STn (sialyl alpha2-6 GalNAc), and TF (Gal beta1-3 GalNAc) carbohydrates. In the present study, NMR methods were used to correlate the effects of cryptic glycosylation outside of the PDTRP core epitope region to the recognition and binding of a monoclonal antibody, Mab B27.29, raised against the intact tumor-associated MUC1 mucin. Four peptides were studied: a MUC1 16mer peptide of the sequence Gly1-Val2-Thr3-Ser4-Ala5-Pro6-Asp7-Thr8-Arg9-Pro10-Ala11-Pro12-Gly13-Ser14-Thr15-Ala16, two singly Tn-glycosylated versions of this peptide at either Thr3 or Ser4, and a doubly Tn-glycosylated version at both Thr3 and Ser4. The results of these studies showed that the B27.29 MUC1 B-cell epitope maps to two separate parts of the glycopeptide, the core peptide epitope spanning the PDTRP sequence and a second (carbohydrate) epitope comprised of the Tn moieties attached at Thr3 and Ser4. The implications of these results are discussed within the framework of developing a glycosylated second-generation MUC1 glycopeptide vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12146959     DOI: 10.1021/bi012176z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  O-glycosylation on cerebrospinal fluid and plasma apolipoprotein E differs in the lipid-binding domain.

Authors:  Sarah A Flowers; Oliver C Grant; Robert J Woods; G William Rebeck
Journal:  Glycobiology       Date:  2020-01-28       Impact factor: 4.313

2.  Significance of Proline Residue on Short Mucin Peptide Interactions with Mouse MUC1 Monoclonal Antibody Studied by Saturation Transfer Difference NMR Spectroscopy.

Authors:  Cheng Her; William M Westler; Thao Yang
Journal:  JSM Chem       Date:  2013-10-17

3.  Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16).

Authors:  Zach T Berman; Lee J Moore; Kathleen E Knudson; Rebecca J Whelan
Journal:  Tumour Biol       Date:  2010-06-22

4.  Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface.

Authors:  Qicheng Zhao; Xiuli Guo; Gerard B Nash; Philip C Stone; John Hilkens; Jonathan M Rhodes; Lu-Gang Yu
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

5.  Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.

Authors:  Emmanuel T Akporiaye; Deborah Bradley-Dunlop; Sandra J Gendler; Pinku Mukherjee; Cathy S Madsen; Tobias Hahn; David G Besselsen; Sharon M Dial; Haiyan Cui; Katrina Trevor
Journal:  Vaccine       Date:  2007-07-24       Impact factor: 3.641

6.  MUC1 is involved in trophoblast transendothelial migration.

Authors:  Twanda L Thirkill; Tim Cao; Michael Stout; Thomas N Blankenship; Abdul Barakat; Gordon C Douglas
Journal:  Biochim Biophys Acta       Date:  2007-04-20

Review 7.  Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer.

Authors:  Nicholas Thatcher; Jim Heighway
Journal:  Oncologist       Date:  2010-10-07

8.  Lentiviral-mediated delivery of classical swine fever virus Erns gene into porcine kidney-15 cells for production of recombinant ELISA diagnostic antigen.

Authors:  Supriya Bhattacharya; Mohini Saini; Deepika Bisht; Mashidur Rana; Ram Bachan; Sophia M Gogoi; Bijoy M Buragohain; Nagendra N Barman; Praveen K Gupta
Journal:  Mol Biol Rep       Date:  2019-04-23       Impact factor: 2.742

9.  Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.

Authors:  P Ruf; O Gires; M Jäger; K Fellinger; J Atz; H Lindhofer
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

10.  Structural and thermodynamic approach to peptide immunogenicity.

Authors:  Carlos J Camacho; Yasuhiro Katsumata; Dana P Ascherman
Journal:  PLoS Comput Biol       Date:  2008-11-21       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.